BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-56@catalystbrief.girapphe.com
DTSTAMP:20261117T061552Z
LAST-MODIFIED:20261117T061552Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Suzhou Suncadia Biopharmaceuticals Co.\, Ltd. — SHR-A200
 9 monotherapy [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Study of SHR-A2009 Versus Platinu
 m-based Chemotherapy in EGFR-mutated\, Advanced or Metastatic NSCLC.\nSour
 ce: https://clinicaltrials.gov/study/NCT06671379\nhttps://catalystbrief.gi
 rapphe.com/e/56?lang=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/56?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
